When it comes to treating Takayasu arteritis, one size doesn't fit all. A new study found that younger patients tend to respond better to TNF inhibitors, while older patients fare better with tocilizumab — and most patients who switch after a failed first treatment still find success. The findings push back against a uniform biologic hierarchy in favor of a more individualized approach.
When it comes to treating Takayasu arteritis, age at onset may be the key to picking the right biologic.
A new study combining data from 151 patients across NIH and an Italian hospital found that TNF inhibitors and tocilizumab performed similarly overall in treating Takayasu arteritis — but age at symptom onset told a more nuanced story. Younger patients responded better to TNF inhibitors, while older patients were more likely to respond to tocilizumab. Importantly, when the first biologic failed, most patients still responded after switching — 15 of 17 who switched to tocilizumab responded, and all 5 who switched to a TNF inhibitor responded.
The researchers also found that patients with symptom onset at age 30 or younger had higher levels of TNF-beta, potentially explaining the biological basis for their stronger response to TNF inhibitors.
By the Numbers:
Why it matters: These findings challenge the idea of a fixed treatment hierarchy for Takayasu arteritis and support a more personalized approach — using age at onset as a practical guide to biologic selection from the start.
